LifeTech Scientific Corporation (HK:1302) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
LifeTech Scientific Corporation has announced the successful completion of a one-year follow-up study for its IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System, showcasing impressive safety and effectiveness results. With a target lesion failure rate of 2.9% and zero cardiac deaths reported, the innovative scaffold is poised for CE registration approval in the European Union. This development promises significant advancements for patients with coronary heart disease worldwide.
For further insights into HK:1302 stock, check out TipRanks’ Stock Analysis page.